Results 21 to 30 of about 1,247,684 (370)

Increased survival with enzalutamide in prostate cancer after chemotherapy.

New England Journal of Medicine, 2012
BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth.
H. Scher, K. Fizazi, F. Saad, M. Taplin, C. Sternberg, K. Miller, R. de Wit, P. Mulders, K. Chi, N. Shore, A. Armstrong, T. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. D. de Bono   +19 more
semanticscholar   +1 more source

Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma

Neoplasia: An International Journal for Oncology Research, 2015
Vascular endothelial growth factor (VEGF)–targeted antiangiogenic therapy significantly inhibits the growth of clear cell renal cell carcinoma (RCC).
Kyung Seok Han, Peter A. Raven, Sebastian Frees, Kilian Gust, Ladan Fazli, Susan Ettinger, Sung Joon Hong, Cristian Kollmannsberger, Martin E. Gleave, Alan I. So   +9 more
doaj   +1 more source

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen

The World Journal of Men's Health, 2023
Purpose: Prostate cancer (PCa) screening can lead to potential over-diagnosis/over-treatment of indolent cancers. There is a need to optimize practices to better risk-stratify patients.
Zoe D. Michael, Srinath Kotamarti, Rohith Arcot, Kostantinos Morris, Anand Shah, John Anderson, Andrew J. Armstrong, Rajan T. Gupta, Steven Patierno, Nadine J. Barrett, Daniel J. George, Glenn M. Preminger, Judd W. Moul, Kevin C. Oeffinger, Kevin Shah, Thomas J. Polascik   +15 more
doaj   +1 more source

Development of a Novel Robot for Transperineal Needle Based Interventions: Focal Therapy, Brachytherapy and Prostate Biopsies [PDF]

Journal of Urology 188 (2012) 1369-1374, 2012
Purpose: We report what is to our knowledge the initial experience with a new 3-dimensional ultrasound robotic system for prostate brachytherapy assistance, focal therapy and prostate biopsies. Its ability to track prostate motion intraoperatively allows it to manage motions and guide needles to predefined targets.
arxiv   +1 more source

Abiraterone and increased survival in metastatic prostate cancer.

New England Journal of Medicine, 2011
BACKGROUND Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with ...
J. D. de Bono, C. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K. Chi, Robert J. Jones, O. Goodman, F. Saad, J. Staffurth, P. Mainwaring, S. Harland, T. Flaig, Thomas E. Hutson, T. Cheng, H. Patterson, J. Hainsworth, C. Ryan, C. Sternberg, S. Ellard, A. Fléchon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C. Haqq, H. Scher   +31 more
semanticscholar   +1 more source

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

npj Precision Oncology, 2023
Specific classes of DNA damage repair (DDR) defect can drive sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker approaches based on DDR gene sequencing do not accurately predict DDR deficiency or treatment benefit ...
Elie J. Ritch, Cameron Herberts, Evan W. Warner, Sarah W. S. Ng, Edmond M. Kwan, Jack V. W. Bacon, Cecily Q. Bernales, Elena Schönlau, Nicolette M. Fonseca, Veda N. Giri, Corinne Maurice-Dror, Gillian Vandekerkhove, Steven J. M. Jones, Kim N. Chi, Alexander W. Wyatt   +14 more
doaj   +1 more source

Screening and prostate-cancer mortality in a randomized European study.

New England Journal of Medicine, 2009
BACKGROUND The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer.
F. Schröder, J. Hugosson, M. Roobol, T. Tammela, S. Ciatto, V. Nelen, M. Kwiatkowski, M. Luján, H. Lilja, M. Zappa, L. Denis, F. Recker, A. Berenguer, L. Määttänen, C. Bangma, G. Aus, A. Villers, X. Rébillard, T. H. van der Kwast, B. G. Blijenberg, S. Moss, H. D. de Koning, A. Auvinen   +22 more
semanticscholar   +1 more source

Cloning of a novel receptor expressed in rat prostate and ovary.

Proceedings of the National Academy of Sciences of the United States of America, 1996
We have cloned a novel member of the nuclear receptor superfamily. The cDNA of clone 29 was isolated from a rat prostate cDNA library and it encodes a protein of 485 amino acid residues with a calculated molecular weight of 54.2 kDa.
G. Kuiper, E. Enmark, M. Pelto-huikko, S. Nilsson, J. Gustafsson   +4 more
semanticscholar   +1 more source

Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours

BMC Cancer, 2018
Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).
Nicola J. Lawrence, Howard Chan, Guy Toner, Martin R. Stockler, Andrew Martin, Sonia Yip, Nicole Wong, Annie Yeung, Danish Mazhar, Farzana Pashankar, Lindsay Frazier, Ray McDermott, Roderick Walker, Hsiang Tan, Ian D. Davis, Peter Grimison, on behalf of ANZUP   +16 more
doaj   +1 more source

PROSTATITIS. [PDF]

JAMA: The Journal of the American Medical Association, 1903
n ...
openaire   +2 more sources